An Open-label, Phase 1, Multicentre Platform Study to Evaluate the Safety and Preliminary Anti-tumour Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Participants With Advanced Malignancies That Are Positive for the TP53 R175H Mutation
This early-stage study is testing a new experimental treatment called NT-175 for adults with advanced cancers. The treatment uses modified immune cells to specifically target a genetic change known as the TP53 R175H mutation.
Adults aged 18 and older who have specific types of advanced cancer, such as colorectal, pancreatic, or breast cancer, may be able to join. Participants must also meet certain genetic and health requirements to ensure safety.
Participants will receive the experimental cell therapy and be closely monitored by the medical team for safety and to see how well the treatment fights the cancer.
This study is currently recruiting patients at medical centers in locations including Arizona and California in the United States.
- 1Testing a new engineered cell therapy for advanced cancers.
- 2Specifically looks for the TP53 R175H genetic mutation.
- 3Currently recruiting participants at select U.S. locations.
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.